BioD, LLC received its first patent for one of its platform tissue technologies. On January 13, 2015, the US Patent and Trademark Office issued US Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable Tissue Matrix product family, a cryopreserved allograft product derived from human placental tissues that is used as a wound covering in the treatment of localized tissue defects or areas of inflammation.

Placental tissues, including the amniotic lining of the placenta, have been used in wound dressings for more than 100 years. Allografts made from placental tissues rarely trigger an immune response in the recipient, are anti-inflammatory, anti-microbial, and anti-adhesive, and provide a unique matrix that may support growth of new cells for improved healing. BioD’s new patent covers the company’s unique method of processing placental tissues to create cryopreserved tissue allografts that preserve these innate characteristics in a form that physicians can utilize for localized tissue repair and reconstruction.

BioD’s allografts provide a natural alternative to synthetic, cadaveric, or animal derived regenerative products and may be used in a broad range of clinical applications, including the treatment of complex chronic wounds, acute wounds such as decubitus or pressure ulcers, or localized areas of injury or inflammation; filling of soft tissue defects or voids, and post-operative wound care.

Timothy Brahm, BioD Founder, Chairman of the Board and Chief Development Officer, says, “We are pleased the patent office has recognized the novel aspects of our methods to preserve the innate regenerative properties of placental tissues. Gaining patent protection for our tissue processing method not only validates and reinforces the unique and valuable nature of this invention, but also protects the value of our company’s intellectual property and our unique portfolio of placental-derived allograft products.”